| Wang, Zhen Jun |
BHV3000-318, NCT05371652: A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants |
|
|
| Completed | 3 | 241 | RoW | Rimegepant 75mg Orally Disintegrating Tablets (ODT) | Pfizer, Bioshin (Shanghai) Consulting Services Co., Ltd | Acute Migraine | 02/24 | 02/24 | | |
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
NCT06295432: A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) |
|
|
| Recruiting | 2 | 90 | RoW | DZD9008+AZD4205, Inapplicable | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 06/25 | 06/25 | | |
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 2 | 170 | RoW | abexinostat | Xynomic Pharmaceuticals, Inc. | Diffuse Large B-cell Lymphoma (DLBCL) | 12/24 | 05/25 | | |
NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 2 | 121 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma | 11/25 | 11/25 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853 |
|
|
| Recruiting | 1/2 | 254 | US, RoW | HH2853 Tablets | Haihe Biopharma Co., Ltd. | FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor | 12/25 | 12/25 | | |
NCT06139536: Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients |
|
|
| Recruiting | 1 | 210 | RoW | BAT4706 Injection, Fc-glycosylated recombinant fully humanized anti-CTLA-4 monoclonal antibody injection, BAT1308 Injection, Recombinant humanized anti PD-1 monoclonal antibody injection | Bio-Thera Solutions | Advanced Solid Tumor | 12/25 | 02/26 | | |
NCT05982080: A Study to Investigate FP002 in Subjects With Advanced Malignancies |
|
|
| Recruiting | 1 | 27 | RoW | FP002 Injection | Guangdong Fapon Biopharma Inc. | Advanced Solid Tumor | 04/25 | 07/26 | | |
